Blood Products Advisory Committee; Amendment of Notice, 68280-68281 [2014-26969]
Download as PDF
68280
Federal Register / Vol. 79, No. 220 / Friday, November 14, 2014 / Notices
TABLE 2—OVERVIEW OF DATA COLLECTION PROCESS FOR ALONE AND TOGETHER CONDITIONS
Viewing condition
Steps
Alone
Together
1 ...........................
Consumer completes prequestionnaire ..................................
2 ...........................
3 ...........................
Consumer views advertising stimuli alone ..............................
Break .......................................................................................
4 ...........................
Consumer completes postquestionnaire .................................
Consumer and spouse complete prequestionnaire separately (spouse completes selected measures).
Consumer and spouse view advertising stimuli together.
Couples engage in a 5-minute semistructured conversation
related to the advertising stimuli.
Consumer and spouse complete postquestionnaire separately (spouse completes selected measures).
To examine differences between
experimental conditions, we will
conduct inferential statistical tests such
as analysis of variance. With the sample
size described below, we will have
sufficient power to detect small-tomedium sized effects in the main study.
FDA estimates the burden of this
collection of information as follows:
TABLE 3—ESTIMATED ANNUAL REPORTING BURDEN 1
Number of
respondents
Activity
Number of
responses per
respondent
Total annual
responses
Average
burden per
response
Total
hours
Pretesting
Number to complete the screener ...................................................
700
1
700
Number of completes .......................................................................
120
1
120
Number to complete the screener ...................................................
4,060
1
4,060
Number of completes .......................................................................
792
1
Total ..........................................................................................
........................
........................
0.08
(5 minutes)
1
56
120
Main study
1 There
FOR FURTHER INFORMATION CONTACT:
[FR Doc. 2014–26918 Filed 11–13–14; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2014–N–1617]
Blood Products Advisory Committee;
Amendment of Notice
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing an
amendment to the notice of the meeting
of the Blood Products Advisory
Committee. This meeting was
announced in the Federal Register of
October 22, 2014. The amendment is
being made to reflect a change in the
Agenda portion of the document. There
are no other changes.
SUMMARY:
mstockstill on DSK4VPTVN1PROD with NOTICES
........................
........................
1,293
792
are no capital costs or operating and maintenance costs associated with this collection of information.
Dated: November 7, 2014.
Leslie Kux,
Assistant Commissioner for Policy.
AGENCY:
325
792
0.08
(5 minutes)
1
VerDate Sep<11>2014
17:37 Nov 13, 2014
Jkt 235001
Bryan Emery or Joanne Lipkind, Center
for Biologics Evaluation and Research,
Food and Drug Administration, 10903
New Hampshire Ave., Bldg. 71, Rm.
6132, Silver Spring, MD 20993, 240–
402–8054 or 240–402–8129, or FDA
Advisory Committee Information Line,
1–800–741–8138 (301–443–0572 in the
Washington, DC area). A notice in the
Federal Register about last minute
modifications that impact a previously
announced advisory committee meeting
cannot always be published quickly
enough to provide timely notice.
Therefore, you should always check the
Agency’s Web site at https://
www.fda.gov/AdvisoryCommittees/
default.htm and scroll down to the
appropriate advisory committee meeting
link, or call the advisory committee
information line to learn about possible
modifications before coming to the
meeting.
In the
Federal Register of October 22, 2014 (79
FR 63131), FDA announced that a
meeting of the Blood Products Advisory
Committee would be held on December
SUPPLEMENTARY INFORMATION:
PO 00000
Frm 00072
Fmt 4703
Sfmt 4703
2 and 3, 2014. On page 63131, in the
third column, the Agenda portion of the
document is changed to read as follows:
Agenda: On December 2, 2014, the
Committee will meet in open session to
hear scientific data related to
reconsideration of the current blood
donor deferral policy for men who have
had sex with another man (MSM) even
one time since 1977. The Committee
will be presented with an update on the
November 13, 2014, meeting of the U.S.
Department of Health and Human
Services Advisory Committee on Blood
and Tissue Safety and Availability
where the MSM blood donor deferral
policy will be discussed. In the
afternoon, the Committee will hear an
informational presentation on Ebola
virus, the potential implications for
blood safety in the United States and
FDA’s considerations on the collection
of convalescent plasma for
investigational use.
On December 3, 2014, the Blood
Products Advisory Committee will be
seated as a device classification panel.
In open session, the panel will discuss
the appropriate device classification of
E:\FR\FM\14NON1.SGM
14NON1
Federal Register / Vol. 79, No. 220 / Friday, November 14, 2014 / Notices
Dated: November 10, 2014.
Jill Hartzler Warner,
Associate Commissioner for Special Medical
Programs.
[FR Doc. 2014–26969 Filed 11–13–14; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Environmental
Health Sciences; Notice of Closed
Meetings
mstockstill on DSK4VPTVN1PROD with NOTICES
Name of Committee: National Institute of
Environmental Health Sciences Special
Emphasis Panel; Biomonitoring
Technologies.
Date: December 3–4, 2014.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Environmental
Health Sciences, 530 Davis Drive, Keystone
Building, Research Triangle Park, NC 27709
(Virtual Meeting).
Contact Person: Sally Eckert-Tilotta, Ph.D.
Scientific Review Officer, Nat. Institute of
Environmental Health Sciences, Office of
Jkt 235001
Ancillary Clinical Studies in Diabetes
Complications.
Date: December 11, 2014.
Time: 2:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892, (Telephone
Conference Call).
Contact Person: ANN A. JERKINS, Ph.D.,
SCIENTIFIC REVIEW OFFICER, REVIEW
BRANCH, DEA, NIDDK, NATIONAL
INSTITUTES OF HEALTH, ROOM 759, 6707
DEMOCRACY BOULEVARD, BETHESDA,
MD 20892–5452, 301–594–2242, jerkinsa@
niddk.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS).
National Institutes of Health
[FR Doc. 2014–26909 Filed 11–13–14; 8:45 am]
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
17:37 Nov 13, 2014
Program Operations, Scientific Review
Branch, P.O. Box 12233, Research Triangle
Park, NC 27709, (919) 541–1446, eckertt1@
niehs.nih.gov.
Name of Committee: National Institute of
Environmental Health Sciences Special
Emphasis Panel, Mitochondrial and Nuclear
Induced Cross-Talk Perturbations in
Response to Environmental Insults.
Date: December 4–5, 2014.
Time: 8:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Sheraton Imperial Hotel, 4700
Emperor Boulevard, Durham, NC 27703.
Contact Person: Leroy Worth, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Research and
Training, Nat. Institute of Environmental
Health Sciences, P. O. Box 12233, MD EC–
30/Room 3171, Research Triangle Park, NC
27709, 919/541–0670 worth@niehs.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.115, Biometry and Risk
Estimation—Health Risks from
Environmental Exposures; 93.142, NIEHS
Hazardous Waste Worker Health and Safety
Training; 93.143, NIEHS Superfund
Hazardous Substances—Basic Research and
Education; 93.894, Resources and Manpower
Development in the Environmental Health
Sciences; 93.113, Biological Response to
Environmental Health Hazards; 93.114,
Applied Toxicological Research and Testing,
National Institutes of Health, HHS)
Dated: November 6, 2014.
Carolyn Baum,
Program Analyst, Office of Federal Advisory
Committee Policy.
blood establishment computer software
(BECS) and accessories to BECS. Blood
establishment computer software is
currently subject to the premarket
notification (510(k)) provisions of the
Federal Food, Drug, and Cosmetic Act.
In the afternoon, an informational
presentation will be made regarding the
emergence of chikungunya virus
infections in the Western Hemisphere
and potential implications for blood
transfusion safety. The Committee will
also hear an informational presentation
on the first survey of the Rapid Donor
Surveillance (RapidDOS) project on
Middle Eastern Respiratory Syndrome
coronavirus (MERS-CoV)
This notice is issued under the
Federal Advisory Committee Act (5
U.S.C. app. 2) and 21 CFR part 14,
relating to the advisory committees.
VerDate Sep<11>2014
68281
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel, PAR12–265
PO 00000
Frm 00073
Fmt 4703
Sfmt 4703
Dated: November 7, 2014.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2014–26908 Filed 11–13–14; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Library of Medicine; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 USC,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable materials,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Library of
Medicine Special Emphasis Panel; Conflicts
R01/R21/K01.
Date: December 10, 2014.
Time: 12:00 p.m. to 3:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Library of Medicine, 6705
Rockledge Drive, Suite 301, Bethesda, MD
20817, (Telephone Conference Call).
Contact Person: Zoe E. Huang, MD,
Scientific Review Officer, Extramural
Programs, National Library of Medicine, NIH,
6705 Rockledge Drive, Suite 301, Bethesda,
MD 20892–7968, 301–594–4937, huangz@
mail.nih.gov.
E:\FR\FM\14NON1.SGM
14NON1
Agencies
[Federal Register Volume 79, Number 220 (Friday, November 14, 2014)]
[Notices]
[Pages 68280-68281]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-26969]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2014-N-1617]
Blood Products Advisory Committee; Amendment of Notice
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing an
amendment to the notice of the meeting of the Blood Products Advisory
Committee. This meeting was announced in the Federal Register of
October 22, 2014. The amendment is being made to reflect a change in
the Agenda portion of the document. There are no other changes.
FOR FURTHER INFORMATION CONTACT: Bryan Emery or Joanne Lipkind, Center
for Biologics Evaluation and Research, Food and Drug Administration,
10903 New Hampshire Ave., Bldg. 71, Rm. 6132, Silver Spring, MD 20993,
240-402-8054 or 240-402-8129, or FDA Advisory Committee Information
Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area). A
notice in the Federal Register about last minute modifications that
impact a previously announced advisory committee meeting cannot always
be published quickly enough to provide timely notice. Therefore, you
should always check the Agency's Web site at https://www.fda.gov/AdvisoryCommittees/default.htm and scroll down to the appropriate
advisory committee meeting link, or call the advisory committee
information line to learn about possible modifications before coming to
the meeting.
SUPPLEMENTARY INFORMATION: In the Federal Register of October 22, 2014
(79 FR 63131), FDA announced that a meeting of the Blood Products
Advisory Committee would be held on December 2 and 3, 2014. On page
63131, in the third column, the Agenda portion of the document is
changed to read as follows:
Agenda: On December 2, 2014, the Committee will meet in open
session to hear scientific data related to reconsideration of the
current blood donor deferral policy for men who have had sex with
another man (MSM) even one time since 1977. The Committee will be
presented with an update on the November 13, 2014, meeting of the U.S.
Department of Health and Human Services Advisory Committee on Blood and
Tissue Safety and Availability where the MSM blood donor deferral
policy will be discussed. In the afternoon, the Committee will hear an
informational presentation on Ebola virus, the potential implications
for blood safety in the United States and FDA's considerations on the
collection of convalescent plasma for investigational use.
On December 3, 2014, the Blood Products Advisory Committee will be
seated as a device classification panel. In open session, the panel
will discuss the appropriate device classification of
[[Page 68281]]
blood establishment computer software (BECS) and accessories to BECS.
Blood establishment computer software is currently subject to the
premarket notification (510(k)) provisions of the Federal Food, Drug,
and Cosmetic Act. In the afternoon, an informational presentation will
be made regarding the emergence of chikungunya virus infections in the
Western Hemisphere and potential implications for blood transfusion
safety. The Committee will also hear an informational presentation on
the first survey of the Rapid Donor Surveillance (RapidDOS) project on
Middle Eastern Respiratory Syndrome coronavirus (MERS-CoV)
This notice is issued under the Federal Advisory Committee Act (5
U.S.C. app. 2) and 21 CFR part 14, relating to the advisory committees.
Dated: November 10, 2014.
Jill Hartzler Warner,
Associate Commissioner for Special Medical Programs.
[FR Doc. 2014-26969 Filed 11-13-14; 8:45 am]
BILLING CODE 4164-01-P